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Abstract: We describe HIV-1 evolutionary dynamics in the 4
participants from the TDF2-PrEP trial who became HIV-1 infected
while prescribed emtricitabine and tenofovir disoproxil fumarate
(FTC/TDF). At seroconversion, virus diversity in the 2 participants
with detectable drug was only 0.05% (95% confidence intervals: 0.04
to 0.06) and 0.07% (0.06 to 0.08) compared with 2.25% (1.95 to 2.6)
and 0.42% (0.36 to 0.49) in those with no detectable drug and 0.07%–
0.69% in 5 placebo recipients (P . 0.5). At 10 months, diversity in
adherent participants was only 0.37% (0.31 to 0.41) and 0.86% (0.82
to 0.90) compared with 0.5%–1.7% among participants who did not
take FTC/TDF (P . 0.5). Although limited by the small number of
infections that reduced the power to detect differences, we found that
sequences from seroconverters with detectable drug were more
homogeneous than those from placebo or nonadherent seroconverters.
Key Words: single genome amplification, pre-exposure prophy-
laxis, Truvada
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INTRODUCTION
Daily PrEP with FTC/TDF is an effective HIV pre-
vention strategy for persons at high risk of infection.1 In
clinical trials, the level of HIV protection by PrEP was strongly
correlated with antiretroviral (ARV) drug adherence.2 Across
trials, infections in active arms were generally seen in
participants with undetectable drug, although some sero-
converters had measurable drug at the time of the first
laboratory evidence of infection. Suboptimal PrEP adherence
and HIV infection create an opportunity for continued drug
activity during undiagnosed infection and raise questions on
the impact of transient ARV drug pressure on early establish-
ment of infection and acute virus dynamics. In some cohort
studies of acute HIV infection, the degree of virus diversity
during early infection was found to be predictive of the
subsequent disease course3,4. The effect of PrEP on virus
evolutionary dynamics and disease course will likely depend
on the extent of ARV drug activity at the time of infection and
before HIV diagnoses.
The TDF2 was a phase III, randomized, double-
blinded, placebo-controlled clinical trial of daily oral FTC/
TDF among sexually active heterosexual men and women in
Botswana.5 In this trial, the overall protective efficacy in the
modified intention-to-treat analysis was 62.2%.5 In the as-
treated analysis, in which follow-up data for participants were
censored 30 days after their last reported study drug dose, the
protective efficacy was 77.9%, with 4 HIV-1 infections in the
FTC/TDF group and 19 in the placebo group.
In this study, we used single genome amplification
(SGA) and phylogenetic and sequence analysis to create
a virological snapshot of HIV-1 in the 4 cases in the FTC/
TDF arm of the TDF2 trial. We defined the number of
transmitted/founder (T/F) viruses in these 4 infections and
compared virus evolution dynamics during the first year of
infection among the FTC/TDF arm cases and 5 seroconverters
who were not taking study drug.
METHODS
Study Samples
We characterized HIV-1 sequences from the 4 partic-
ipants from TDF2 that seroconverted in the FTC/TDF arm
(1069H, 4108P, 3104V, and 1273P) and from 5 seroconvert-
ers that were not taking study drug (1249F, 3184X, 1177E,
3205B, and 4123Y). Table S1 (see Supplemental Digital
Content, http://links.lww.com/QAI/A779) shows the charac-
teristics of these individuals including gender, plasma drug
levels, and virus load at the seroconversion visit. Two of the 4
FTC/TDF-arm cases (1069H and 4108P) had detectable
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tenofovir (TFV) and FTC in plasma at a visit before and
closest to their estimated seroconversion date, and 2 (3104V
and 1273P) did not have measurable drug in plasma.5 None of
these seroconverters had detectable drug resistance mutations
at the first RNA-positive sample or in any of their samples from
subsequent study visits6. The 5 seroconverters that were not
taking study drug were selected based on sample availability,
plasma HIV-1 viral load, and ability to amplify sequences and
perform SGA. For each participant, HIV RNA was extracted
from plasma samples collected at the seroconversion visit and
a median of 10 months (range: 5–12) later, with the exception of
1273P who was lost to follow up. None of the 9 seroconverters
initiated HAART during this period of observation.
SGA and Sequence Analysis
SGA was performed after a standard protocol obtained
from the Center for HIV/AIDS Vaccine Immunology using
primers specific for HIV subtype C. Serial dilutions of the
reverse transcriptase-generated cDNA were made to identify
dilutions of cDNA resulting in ,30% of positive wells by
polymerase chain reaction. Based on a Poisson distribution,
amplifications at this dilution represent sequences derived
from a single cDNA copy.7 Env sequences (;1 kb)
representing the V1-V5 and flanking regions of HIV env
were generated using an ABI3130xl-automated sequencer.
For each participant, we generated an average of 21
sequences from the seroconversion visit specimens (range:
8–28) and 23 sequences (range: 17–27) from the specimens
collected at a follow-up study visit. All sequences clustered with
an HIV subtype C reference sequence (see Figure S1,
Supplemental Digital Content, http://links.lww.com/QAI/A779).
Phylogenetic Analysis
Sequences were aligned and edited using Geneious
software (version 6.1.6). Phylogenetic analysis was performed
using the MEGA (version 5.0) software package. Nucleotide
alignments were prepared using ClustalW; all indels were
removed from the alignments before phylogenetic analysis.
Phylogenetic trees were inferred using the neighbor joining
(NJ) method and Tamura-Nei substitution model and rooted
with reference HIV sequences from multiple subtypes (A to K).
The number of T/F variants that established infection was
determined by exploring the pattern of env diversity at the
seroconversion visit using the highlighter tool (http://www.hiv.
lanl.gov/content/sequence/HIGHLIGHT/highlighter.html). For
this analysis, we excluded hypermutated sequences and gaps,
and we assumed that variants with 2 or less unique nucleotide
changes arise from the same T/F variant.7 The Poisson-Fitter
tool (http://www.hiv.lanl.gov/content/sequence/POISSON_
FITTER/poisson_fitter.html) was used to confirm infection
with single variants and calculate the time since infection.8
Estimates of evolutionary divergence were performed by
pairwise analysis of T/F virus and later time point sequences
using the maximum composite likelihood method in MEGA5.
Results were expressed as number of nucleotide substitutions
per site per year.9,10 A repeated-measures marginal model
with compound symmetry covariance structure was used to
compare differences in virus diversity or diversification
among participants who seroconverted in the FTC/TDF
arm with participants who were not taking study drug.11
Differences in within-subject variation were studied using the
Wilcoxon test.
RESULTS
Virus Diversity and Estimated Time Since
Infection in the 4 Participants Assigned
to FTC/TDF
Both 1069H and 4108P had detectable TFV and FTC in
plasma at a visit before and closest to their estimated
seroconversion date.5 Figure S2 (see Supplemental Digital
Content, http://links.lww.com/QAI/A779) shows the high-
lighter plots for these 2 participants who demonstrates low
diversity at the seroconversion visit consistent with infection
with a single variant. Poisson-Fitter analysis of seroconversion
visit specimens also supported homogeneous infections with 1
T/F variant and provided an estimated time since infection of
24 days [95% confidence intervals (CI): 11 to 37] for 1069H
and 27 days (95% CI: 11 to 43) for 4108P (Table 1).
HIV infection in the 2 seroconverters without detectable
FTC or TFV (3104V and 1273P), was initiated with multiple
variants; 3 in 3104V and 5 in 1273P (Table 1; see Figure S2,
Supplemental Digital Content, http://links.lww.com/QAI/A779).
Poisson-Fitter analysis of sequences from 1273P further sup-
ported heterogeneous infection, which did not allow an
estimation of the time since infection. We could not apply the
Poisson-Fitter tool to 3104V because the number of bases at
which any 2 sequences differed was too high (mean Hamming
distance = 17.23).
Nucleotide Diversity and Estimated Time
Since Infection in Seroconverters Assigned
to Placebo
Infections in seroconverters assigned to placebo were
initiated with 1 (1249F, 3205B, and 4123Y) or 2 T/F
variants (3184X and 1177E) (see Figure S3, Supplemental
Digital Content, http://links.lww.com/QAI/A779). Esti-
mated time since infection was 43 (95% CI: 24 to 62) days
for 1249F, 23 (12–33) days for 3205B, and 18 (5 to 31) days
for 4123Y (Table 1). We could not calculate the estimated
time since infection in 3184X and 1177E due to
heterogeneous infections.
Virus Diversity and Diversification in
TDF2 Infections
Nucleotide sequences derived from the seroconversion
visit specimens from 1069H and 4108P (detectable plasma
drug levels) were very homogenous with mean nucleotide
diversity values of only 0.05% (95% CI: 0.04 to 0.06) and
0.07% (0.06 to 0.08), respectively (Table 1). These values
were higher for the 2 participants assigned to FTC/TDF but
who had no detectable plasma drug levels [2.25% (1.95 to
2.60) in 3104V and 0.42% (0.36 to 0.49) in 1273P] and in the
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seroconverters that were not taking study drug (median =
0.13%; range = 0.07–0.69).
At study follow-up, nucleotide diversity in 1069H and
4108P was 0.37% (95% CI: 0.31 to 0.41) and 0.86% (0.82 to
0.90) compared with a median of 1.37% (min, max = 0.50 to
1.70) in seroconverters that were not on study drug (Table 1).
A comparison of virus diversity among seroconverters with
detectable plasma drug levels with those that were not on
study drug showed no significant differences either at baseline
or at follow-up (P . 0.5 for each comparison), although this
analysis was limited by the small number of individuals in
each group. Figure 1 shows the cumulative frequencies of
nucleotide substitutions per site and illustrates how the 2
FTC/TDF participants with detectable plasma drug levels at
the seroconversion visit (1069H and 4108P) had low virus
diversity both at baseline and at follow-up.
We also investigated nucleotide divergence from the
most recent common ancestor after a median of 10 months of
infection. Mean nucleotide divergences in 1069H and 4108P
fell within the range observed in seroconverters not taking
study drug (P . 0.5) (Table 1).
DISCUSSION
We investigated acute HIV dynamics in participants
who become infected with HIV during the TDF2-PrEP trial.
We defined virus diversity at seroconversion and after 1 year
of infection using SGA and phylogenetic and sequence
analysis. We found that infections in the 2 participants with
measurable FTC and TFV at their seroconversion visit were
more homogeneous and evolved more slowly than those from
participants who became infected while not taking study drug.
These findings are consistent with early observations in
macaques infected with SHIV during intermittent oral PrEP
with FTC/TDF.12,13 In those studies, continued drug exposure
with 1–2 weekly drug doses during acute SHIV infection was




Since Infection (95% CI)
Mean % Nucleotide Diversity (95% CI) Env Diversification
From MRCA*Seroconversion Visit Follow-up Visit
Participants taking FTC/TDF
Detectable drug
1069H 1 24 (11–37) 0.05 (0.04 to 0.06) 0.37 (0.31 to 0.41) 1.4 · 1022
4108P 1 27 (11–43) 0.07 (0.06 to 0.08) 0.86 (0.82 to 0.90) 0.6 · 1022
Undetectable drug
3104V 3 — 2.25 (1.95 to 2.6) 2.39 (2.23 to 2.52) —
1273P 5 — 0.42 (0.36 to 0.49) n.a. n.a.
Participants not taking FTC/TDF†
1249F 1 43 (24–62) 0.11 (0.10 to 0.12) 1.12 (1.07 to 1.16) 1.0 · 1022
3184X 2 — 0.31 (0.30 to 0.32) 1.37 (1.29 to 1.45) 1.2 · 1022
1177E 2 — 0.69 (0.61 to 0.77) 1.70 (1.56 to 1.83) 1.2 · 1022
3205B 1 23 (12–33) 0.13 (0.12 to 0.14) 0.50 (0.47 to 0.53) 0.3 · 1022
4123Y 1 18 (5–31) 0.07 (0.06 to 0.08) 1.68 (1.60 to 1.77) 3.9 · 1022
Median 1 0.13 1.37 1.2 · 1022
*Nucleotide substitutions per site per year. We could not reliably compute diversification in 3104V because of the existence of 2 very distinct sequences at seroconversion and
preferential expansion of only 1 population.
†Of the 5 seroconverters that were not on FTC/TDF, 4 were in the placebo arm and 1 (1249F) was in the FTC/TDF arm but was infected 30 days after the last reported dose of
study medication.
MRCA, most recent common ancestor; n.a., follow-up samples were not available.
FIGURE 1. Cumulative frequencies of nucleotide substitutions per site in seroconverters from the TDF2 trial. A, Cumulative
frequencies of nucleotide substitutions per site at seroconversion. B, Cumulative frequencies of nucleotide substitutions per site
after a median of 10 (range = 5–12) months.
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associated with limited virus diversity and evolution and
a better preservation of immune responses.12–15 This scenario
in macaques could easily mimic persons who acquire HIV
because of inconsistent PrEP adherence and who continue on
the PrEP regimen until diagnosis. We hypothesize that
transient PrEP exposure may have also limited HIV diversity
in the 2 infections from TDF2 that had detectable FTC and
TDF in plasma. Our estimate of 24 and 27 days from HIV
infection to seroconversion is consistent with the frequency of
HIV testing (monthly) and provides an opportunity for
continuous ARV drug exposure between infection and
diagnoses. Perhaps not surprisingly, viruses for these 2
participants diversified from the most recent common ances-
tor at rates statistically indistinguishable from the rates
observed for the infections that occurred in the absence of
plasma FTC/TDF, likely reflecting FTC/TDF discontinuation
after confirmed HIV diagnoses.
A major limitation of our study was the small number
of seroconversions in the FTC/TDF arm that reduced
statistical power to ,30% and limited our ability to compare
virus diversity and diversification between treatment groups.
Sample size calculations found that for such analysis to have
sufficient power, we would require 12 subjects per group for
a subject-specific comparison of diversity or 6 subjects per
group for a repeated-measures analysis. A recent study also
found statistically insignificant lower viremias in FTC/TDF
seroconverters from TDF2 compared with those assigned to
placebo, although sample size limitations affected the ability
to detect small but potentially significant differences in virus
load set points.6 Thus, although not definitive, all these
findings point to potential virological differences between
PrEP breakthrough infections and HIV infections acquired in
the absence of ARV drugs and stress the need to expand this
type of analysis to other PrEP trials. These studies should also
evaluate if PrEP use at the time of infection may favor single
variant transmission or monospecific expansions of viruses
with fitness advantages in the presence of ARVs.
Our definition of adherence was based on having detect-
able FTC and TFV in the plasma of the seroconversion-visit
blood specimen. All clinical trials of PrEP have demonstrated
that efficacy is strongly associated with adherence, especially
when assessed by plasma drug concentrations.2 A limitation of
this approach is that drug concentrations are measured at
a single time associated with a scheduled clinical encounter,
which may not reflect consistent adherence and is also subject
to a form of social desirability bias whereby less adherent
subjects may be prone to take the study product immediately
before their study visit so as not to disclose their nonadherence.
In summary, we found that among persons who became
HIV-1 infected while taking FTC/TDF PrEP and who at that
time had detectable plasma concentrations of drug, env
sequences were more homogeneous and evolved more slowly
than env sequences isolated from HIV-1 seroconverters who
had no detectable FTC or TFV, or were not taking PrEP. If
confirmed in other PrEP trials, these findings suggest that
transient PrEP exposure during acute infection may have
a measurable effect on virus evolution. Our findings under-
score the need to better understand the potential impact of
PrEP on control of HIV-1 infection.
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